From the first post in June 20216 Sep 2023 16:10
On page 12 - yes, that many in over 2 years lol.
AI driven - state of the art tech.
Looks great. FY20 in +'ve net profit due to BARDA contract.
No private equity debt anywhere. Fantastic.
Moat.
Continued BARDA contract grants if milestones hit.
Extending into Diabetic Foot Ulcers.
IP protected.
Octopus Investments hold 7%.
For their burn wounds triaging - they already have FDA break through status.
SINCE THEN: [THE IPO AT 65P]
$25M GRANTS FROM FED GOV
45% GP MAINTAINED
LISTING ON NASDAQ FUNDED AT LEAST TO END 2024, PROBABLY 2 YEARS MORE
$500M FED GOV CONTRACT ALMOST CERTAIN
NEW FUNDING EQUIV £1
AND yes, SOME ARE STILL SELLING.
The message is clear, AIM is broken and its forced out a stellar company.